Non-alcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Non-alcoholic Fatty Liver Disease.
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the
metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and
non alcoholic steatohepatitis (NASH), as the result of fat accumulation in the liver (liver
fat >5-10% of liver weight), not due to excess alcohol consumption or other causes of
steatosis.
At present, no medication or surgical procedure has been approved for treating NAFLD and
lifestyle modifications remain the cornerstone therapy targeting both at weight reduction for
overweight subjects and at prevention of overweight for the normal weight individuals. Given
that a Mediterranean dietary pattern has a beneficial effect both on the prevention and the
resolution of the metabolic syndrome, the main aim of the present study is to implement and
evaluate the potential benefits of an intervention based on the Mediterranean lifestyle in a
sample of patients with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is a pathologic condition which involves both
hepatic steatosis and non alcoholic steatohepatitis (NASH), as the result of fat accumulation
in the liver (liver fat >5-10% of liver weight), not due to excess alcohol consumption or
other causes of steatosis. Its prevalence ranges in the general population from 10-35%, while
in obese individuals can reach the 75% and is particularly worrying because these people
appear to have a higher mortality from both liver and non-liver-related disease, such as
cardiovascular disease, and therefore a greater economic burden of health costs.
At present, no medication or surgical procedure has been approved for treating NAFLD and
lifestyle modifications remain the cornerstone therapy targeting both at weight reduction for
overweight subjects and at prevention of overweight for the normal weight individuals. Given
that a Mediterranean dietary pattern has a beneficial effect both on the prevention and the
resolution of the metabolic syndrome, the main aim of the present study is to implement and
evaluate the potential benefits of an intervention based on the Mediterranean lifestyle in a
sample of patients with NAFLD. A secondary aim will be to produce material, for both health
professionals (namely dietitians and doctors) and patients to help them implementing such an
intervention based on the Mediterranean lifestyle.
This study will be a prospective, randomized, blinded and controlled study. Participants with
NAFLD and BMI>25Kg/m2 (range 25-40 Kg/m2) will be included. NAFLD's diagnosis will be based
on increased serum levels of alanine aminotransferase (ALT), with or without increased
gamma-glutamyl transpeptidase (GGT) serum levels, the presence of hepatic steatosis and
absence of other causes of hepatic steatosis and hepatic failure.
At baseline, patients will be informed about the study and will give their written consent.
Then subjects will be randomly assigned to one of 3 groups: (a) Control group, receiving
written general advice for a healthy lifestyle; (b) Mediterranean diet Group or (c)
Mediterranean lifestyle group. Participants in (b) and (c) groups will attend a more
comprehensive program, comprising seven 60-min group counseling sessions, conducted every two
weeks for the first 2 months and every month for the following 4 months, until the 6-month
evaluation. Participants will be also assessed 12 months after their entry in the study.
The dietary intervention and the monitoring will be carried out in the laboratory of Clinical
Nutrition & Dietetics at Harokopio University, where experienced clinical dietitians will
conduct all consultations. Counseling will be based on the goal setting theory. Motivational
and behavioral strategies will be also used. In the Mediterranean diet group, all food groups
of the Mediterranean diet will be targeted, whereas in the Mediterranean lifestyle group
culinary practices, seasonality, and locality of food products, socialization during meals,
rest during the day, as well as the adoption of an active living will be additionally
addressed. Intervention will also aim at achieving a 5-10% weight loss within the first 6
months.
Patients will be evaluated at baseline, at the end of the 6-mo intervention and 1 year after
the study entry. At baseline, all patients will undergo a brief medical history assessment,
complete physical examination and routine laboratory testing. History of alcohol consumption
will be obtained from both patients and friends/relatives where possible. Evaluation of
anthropometric measurements, dietary intake, physical activity and lifestyle habits, will be
continuously assessed throughout the study. Dietary intake will be assessed through two
24-hour recalls and a food frequency questionnaire (FFQ). Data from recalls will be analyzed
in terms of energy, macro- and micronutrient intake (using the Nutritionist Pro, version 2.2
software), as well as of food group intake and meal patterns. Conditions around eating will
be also recorded and analyzed. Furthermore, a semi-quantitative FFQ, including the main food
groups of the Mediterranean diet will be used for the overall assessment of eating habits.
Physical activity will be assessed using the Harokopio Physical Activity Questionnaire
(HPAQ). Sleep duration and quality will be evaluated through the Athens Insomnia Scale,
consisting of items related to sleep induction, awakenings during the night, final awakening,
total sleep duration, and sleep quality, well-being, functioning capacity, and sleepiness
during the day. Current and past smoking habits will be also recorded.
At baseline and at 6 and 12 months, blood samples will be collected after an overnight food
deprivation for the assessment of biochemical markers, and stored at -80oC. Lipid profile,
markers of glucose metabolism and liver function, and adipokines, inflammatory markers and
markers of oxidative stress will be determined using automated analyzers and/or commercial
ELISA kits.
All patients will pass through liver stiffness measurements with liver elastography at
baseline, as well as at the end of the intervention and after one year of the study entry.
Patients without a recent liver biopsy (within the previous 12 months) will also undergo
liver biopsy at baseline. Liver biopsies will be repeated one year after and will be
evaluated by the same hepato-pathologist, who will have access to patient's clinical data.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04481594 -
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06151964 -
A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese
|
Phase 1/Phase 2 | |
Completed |
NCT04019561 -
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
|
Phase 2 | |
Completed |
NCT01694849 -
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
Completed |
NCT03517540 -
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
|
Phase 2 | |
Withdrawn |
NCT05050721 -
Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
|
||
Active, not recruiting |
NCT04682600 -
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
|
N/A | |
Enrolling by invitation |
NCT01950884 -
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
|
Phase 4 | |
Completed |
NCT04483947 -
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
|
Phase 1 | |
Completed |
NCT02927314 -
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT02612662 -
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT06168383 -
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .
|
Phase 2 | |
Terminated |
NCT02605616 -
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 2 | |
Completed |
NCT02158351 -
Gut Microbiota and Modulation of Liver Damage in NAFLD
|
||
Recruiting |
NCT03151473 -
Longitudinal Observational Study Of Chinese With NAFLD/NASH
|
||
Recruiting |
NCT04820036 -
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
|
N/A | |
Recruiting |
NCT05553470 -
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
|
Phase 1 | |
Recruiting |
NCT04639414 -
Combined Active Treatment in Type 2 Diabetes With NASH
|
Phase 4 | |
Withdrawn |
NCT04607655 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
|
Phase 1/Phase 2 |